The Latest Breaking News from Boston Scientific

Boston Scientific to pay $105m to Australian women who received pelvic mesh implants

Lawyer says settlement will provide compensation for women who suffered pain and complications from pelvic mesh

The Guardian - AU · Jul 13, 2022

How Is The Market Feeling About Boston Scientific?

Boston Scientific's (NYSE:BSX) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short, which is 1.35% of all regular shares that are available for trading.

Benzinga · Jun 29, 2022

Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

Benzinga · Jun 27, 2022

Where Boston Scientific Stands With Analysts

Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:

Benzinga · May 27, 2022

If You Invested $1000 In Boston Scientific 10 Years Ago, Here's How Much You Would Have Today

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.68% on an annualized basis producing an average annual return of 21.79%. Currently, Boston Scientific has a market capitalization of $58.91 billion.

Benzinga · May 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2022

Upgrades

Benzinga · May 27, 2022

This Foreboding Sign Looms Over Boston Scientific's Chart

If history is any guide, there may be trouble ahead for shares of Boston Scientific (NYSE:BSX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga · May 16, 2022

5 Analysts Have This to Say About Boston Scientific

Boston Scientific (NYSE:BSX) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 28, 2022

Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

Boston Scientific Corp (NYSE:BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of approximately 5% - 8%. The Company achieved…

Benzinga · Apr 27, 2022

Recap: Boston Scientific Q1 Earnings

  Boston Scientific (NYSE:BSX) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Boston Scientific reported in-line EPS of $0.39 versus an estimate of $0.39.

Benzinga · Apr 27, 2022